Percorrer por data de Publicação, começado por "2021-07-11"
A mostrar 1 - 1 de 1
Resultados por página
Opções de ordenação
- MCT1 is a new prognostic biomarker and its therapeutic inhibition boosts response to Temozolomide in human glioblastomaPublication . Gonçalves, Vera Miranda; Gonçalves, Céline S.; Granja, Sara; Castro, Joana Vieira de; Reis, Rui M.; Costa, Bruno M.; Baltazar, Fátima; Granja, SaraGlioblastoma, the brain tumour with highest prevalence and lethality, exhibits a characteristic glycolytic phenotype with increased lactate production. Recently, we reported a MCT1 overexpression in GBMs tumours, being associated to tumour growth and aggressiveness. Thus, we aimed to disclose the role of MCT1 in GBM prognosis and in vivo therapy response. Importantly, MCT1 overexpression is associated with poor prognosis of GBM. Moreover, MCT1 inhibition retards GBM tumour growth and boosts response to temozolomide treatment.